- Trials with a EudraCT protocol (6)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    6 result(s) found for: Congenital hydrocephalus.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2011-003325-10 | Sponsor Protocol Number: 1.01 | Start Date*: 2012-08-10 | |||||||||||||||||||||
| Sponsor Name:VU University Medical Center | |||||||||||||||||||||||
| Full Title: A randomized controlled trail on the effects of periconceptional and prenatal folic acid supplementation on congenital anomalies and preterm birth | |||||||||||||||||||||||
| Medical condition: congenital anomalies | |||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2012-005295-33 | Sponsor Protocol Number: S54913 | Start Date*: 2013-03-08 | |||||||||||
| Sponsor Name:UZ Leuven-Department of Urology | |||||||||||||
| Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity. | |||||||||||||
| Medical condition: children with neurogenic detrusor overactivity | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003842-18 | Sponsor Protocol Number: A301223 | Start Date*: 2014-04-24 | |||||||||||||||||||||
| Sponsor Name:Erasmus MC | |||||||||||||||||||||||
| Full Title: Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study. | |||||||||||||||||||||||
| Medical condition: Neurogenic bladder function disease in spina bifida patients. | |||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-006433-13 | Sponsor Protocol Number: TNG-CL008 | Start Date*: 2008-06-11 | ||||||||||||||||
| Sponsor Name:Tengion Inc. | ||||||||||||||||||
| Full Title: An open-label, multicentre study of augmentation cystoplasty using an autologous Neo-Bladder construct in subjects with spina bifida. | ||||||||||||||||||
| Medical condition: Neurogenic bladder secondary to spina bifida | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-006997-27 | Sponsor Protocol Number: CRAD001M2301 | Start Date*: 2011-06-01 | 
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) | ||
| Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC). | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002924-35 | Sponsor Protocol Number: APHP180592 | Start Date*: 2021-01-18 | 
| Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | ||
| Full Title: Prenatal treatment of congenital cytomegalovirus infection with letermovir randomized against valaciclovir | ||
| Medical condition: Step 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP Step 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-ta... | ||
| Disease: | ||
| Population Age: Children, Under 18, Adults | Gender: Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.